Alchemab’s new CEO is the company’s co-founder and hitherto CSO, Jane Osbourn.
AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics ...
When AstraZeneca acquired MedImmune in 2007 for $15 billion, some analysts felt the firm overpaid for the biotech company. This week, MedImmune celebrates its 25th anniversary – and has come to ...
( MENAFN - PR Newswire) NEW YORK, Sept. 23, 2024 /PRNewswire/ -- MTS health Partners ("MTS") announced today that healthcare investment banker Aaron Schwimmer has joined their global life sciences ...
The Minnesota Department of Health has reported two variant H3N2 (H3N2v) flu infections, both involving young people who ...